Olympus ups venture capital fund by $150m for MedTech innovation

Olympus Corporation announced on December 15, 2025, an additional $150 million investment in its corporate venture capital fund, Olympus Innovation Ventures Fund II ("OIV Fund II"). This funding reinforces Olympus's recently unveiled corporate strategy, aiming for innovation-driven growth with an annual revenue increase of 3-5%. OIV Fund II will continue to build relationships with early-stage companies and foster partnerships with entrepreneurial teams relevant to Olympus's strategic focus, including OLYSENSE and robotics.

Olympus Innovation Ventures, LLC, headquartered in Westborough, MA, is a wholly-owned consolidated subsidiary of Olympus Corporation of the Americas. The total investment for OIV Fund II is now $200 million, which includes the initial commitment of $50 million for OIV Fund I. The additional $150 million is projected to be deployed over several years, dependent on identified investment opportunities.

Olympus anticipates that OIV Fund II will not materially impact its financial results for the fiscal year ending March 31, 2026. The fund will identify, vet, and invest in early-stage companies with differentiated technologies, mirroring the strategy of OIV Fund I.